Therapeutic Drug Delivery
Therapeutic Drug Delivery - Related Videos
05:10
Intrarenal Drug Delivery in Rats: A Method to Deliver Therapeutic Drugs in Rat Kidney via Intra-arterial Injection
0 Views •
2023
In this video, we demonstrate intra-renal drug administration in rats via the renal artery. This method is beneficial in improving drug targeting, drug potency, and minimizing systemic toxicity.
10:33
Delivery of Therapeutic siRNA to the CNS Using Cationic and Anionic Liposomes
0 Views •
Cited by 18 •
2016
The goal of this protocol is to use cationic/anionic liposomes with a neuro-targeting peptide as a CNS delivery system to enable siRNA to cross the BBB. The optimization of a delivery system for treatments, like siRNA, would allow for more treatment options for prion and other neurodegenerative diseases.
02:24
Microinjection-Based Delivery of a Therapeutic Agent into an Awake Rodent Brain
0 Views •
2025
Source: Poland, R. et al. Rodent Brain Microinjection to Study Molecular Substrates of Motivated Behavior. J. Vis. Exp. (2015)In this video, a water-filled microinjection setup consisting of a syringe and microinjector tubing is used for precise drug delivery. A rat with a pre-implanted guide cannula undergoes targeted brain microinjection, enabling accurate administration of therapeutic agents in awake animals with minimal tissue damage.
05:53
Intraluminal Drug Delivery to the Mouse Arteriovenous Fistula Endothelium
0 Views •
Cited by 5 •
2016
After puncturing the aorta through the inferior vena cava (IVC) to create an aorto-caval fistula in the mouse, solution containing a drug is infused into the IVC via the same needle, followed by incubation. This method enables more robust drug delivery to the venous endothelium compared to the external route.
01:33
Nanoparticle-Mediated Enhanced Delivery of an Anti-Inflammatory Drug in Microglia-Like Cells
0 Views •
2025
Take cultures of human monocyte-derived microglia-like cells.Introduce nanoparticles containing an anti-inflammatory drug into the experimental culture and the free drug into the control.The nanoparticles feature a hydrophilic shell and a hydrophobic core encapsulating the lipophilic drug.The cells endocytose the nanoparticles, which release the drug intracellularly, enhancing its delivery.The free drug enters by passive diffusion, a process constrained by the concentration gradient, which...
FAQs
Formulation, delivery route, release behavior, and targeting mechanisms jointly shape absorption, distribution, stability, and cellular uptake. Changing one variable can alter whether a medicine reaches infected tissue, remains available at an effective concentration, or enters a relevant immune cell population. Researchers therefore consider these features together rather than treating delivery route or formulation as an isolated choice.
Release mechanisms control when and for how long a medicine becomes available, while targeting mechanisms influence where it accumulates or which cells take it up. Coordinating these functions can help maintain effective concentrations at a desired site and limit unnecessary exposure elsewhere. This is particularly relevant when treatment must reach infected tissues or specific immune cell populations.
Biological barriers can restrict transport, reduce stability, or limit cellular uptake before a medicine reaches its intended site. Therapeutic drug delivery addresses these constraints by combining an appropriate formulation, route, and release or targeting strategy. Overcoming such barriers may improve access to infected tissues, support treatment of persistent infections, and reduce systemic toxicity.
Design begins by identifying the therapeutic objective, such as reaching infected tissue, an immune cell population, or maintaining exposure for an appropriate duration. Researchers then align the drug formulation with a delivery route and select release or targeting mechanisms. The resulting system is considered in terms of site, concentration, stability, cellular uptake, and potential toxicity.
These systems can be applied to antimicrobials, vaccines, immunomodulators, and biologics. Their value depends on matching the delivery strategy to the biological problem, whether that involves infection, persistent microbial exposure, or a dysregulated immune response. More precise transport may improve therapeutic effectiveness while reducing systemic toxicity and increasing access to relevant tissues or cells.
Evaluation should consider whether the medicine reaches the intended site, achieves effective concentrations, remains available for an appropriate duration, and retains sufficient stability. Cellular uptake and systemic toxicity also provide important evidence of performance. Together, these outcomes show whether the delivery system improves therapeutic precision and helps address biological barriers relevant to infection or immune dysfunction.